Hemab Therapeutics (NASDAQ:COAG) Shares Gap Up - Time to Buy?

Key Points

• Hemab Therapeutics shares jumped: COAG opened at $32.16 versus a prior close of $30.07 and last traded at $33.03, though the stock remained below its 50-day moving average of $40.52.
• Analyst sentiment is largely bullish: Seven analysts rate the stock Buy, compared with one Hold and one Sell, with a Moderate Buy consensus and an average price target of $54.71.
• Fundamentals remain speculative: Hemab reported a quarterly loss of $0.80 per share, missing estimates by $0.17, while several institutional investors—including Braidwell and State Street—recently initiated positions.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $30.07, but opened at $32.16. Hemab Therapeutics shares last traded at $33.03, with a volume of 11,407 shares traded.

Wall Street Analysts Forecast Growth

COAG has been the subject of several recent research reports. Jefferies Financial Group upped their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Weiss Ratings downgraded Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, September 25th. HC Wainwright raised their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Wedbush lifted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Finally, Rodman & Renshaw began coverage on Hemab Therapeutics in a research note on Monday, October 12th. They set a "buy" rating and a $56.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Hemab Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $54.71.

Hemab Therapeutics Stock Performance

The firm has a market capitalization of $1.55 billion and a P/E ratio of -1.34. The firm has a 50-day moving average price of $40.52.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). On average, equities research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.10 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics during the second quarter worth $230,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Hemab Therapeutics during the second quarter worth $688,000. Opaleye Management Inc. bought a new stake in Hemab Therapeutics in the 2nd quarter valued at $1,750,000. State Street Corp bought a new stake in Hemab Therapeutics in the 2nd quarter valued at $2,825,000. Finally, Braidwell LP bought a new stake in Hemab Therapeutics in the 2nd quarter valued at $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics NASDAQ: COAG is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab's lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.